Skip to main content

Market Overview

FDA Rejects Eagle Pharma's Vasopressin Application

  • The FDA has issued a complete response letter (CRL) for Eagle Pharmaceuticals Inc's (NASDAQ: EGRX) abbreviated marketing application seeking vasopressin approval.
  • The company had two conversations with FDA regarding the rejection letter and will have an additional meeting with the agency within 30 days. Eagle Pharma says that it has completed developmental work and continues to do so for its first-to-file polypeptide, where annual brand sales of the product are over $700 million.
  • In its communication with Eagle Pharma, the FDA restated that it has prioritized Eagle's vasopressin application, and it is also flagged as a COVID-19 priority.
  • The company will have to conduct one additional short-duration study that will take place either in mid-February or mid-March. Also, Eagle Pharma expects to have 180 days of exclusivity.
  • Separately, the patent trial case against Endo Par Innovation Company, LLC is now scheduled to begin on July 7. Par's asserted patents claim a formulation with a pH of 3.7-3.9, while Eagle's proposed product specifies a pH outside of that range.
  • Price Action: EGRX shares closed higher by 3.90% at $48.49 on Monday.

Related Articles (EGRX)

View Comments and Join the Discussion!

Posted-In: FDA CRL VasopressinBiotech News Small Cap FDA Top Stories General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at